Arthritic drug bariticinib effective in reducing covid 19 deaths
Recent RECOVERY Trial said Eli Lilly and Incyte's arthritis drug baricitinib helped reduce the risk of death in hospitalised COVID-19 patients by 13% regardless of which other coronavirus treatment they were given, according to a large British study. Results showed 546 patients in the usual care group died within 28 days but only 513 patients in the baricitinib group died where they were also...
Recent RECOVERY Trial said Eli Lilly and Incyte's arthritis drug baricitinib helped reduce the risk of death in hospitalised COVID-19 patients by 13% regardless of which other coronavirus treatment they were given, according to a large British study. Results showed 546 patients in the usual care group died within 28 days but only 513 patients in the baricitinib group died where they were also given a corticosteroid like dexamethasone, tocilizumab or remdesivir.
Scientists and doctors welcomed the addition of Baricitinib to the few treatments already shown to help treat severe COVID-19. Baricitinib inhibits Janus kinase (JAK) enzymes, which are intracellular enzymes involved in stimulating hematopoiesis and immune cell function.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd